BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2020 5:58:43 AM | Browse: 757 | Download: 1351
 |
Received |
|
2020-06-09 03:09 |
|
Peer-Review Started |
|
2020-06-09 03:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-18 16:46 |
|
Revised |
|
2020-10-07 00:16 |
|
Second Decision |
|
2020-11-13 09:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-11-13 19:17 |
|
Articles in Press |
|
2020-11-13 19:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-12-04 08:23 |
|
Publish the Manuscript Online |
|
2020-12-18 05:58 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson and Yousaf Zafar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Shafiq, MD, Assistant Professor, General and Geriatric Medicine, University of Kansas Medical Center, 4000 Cambridge Street, 6040 Delp & Mail Stop 1020, Kansas City, KS 66160, United States. mshafiq@kumc.edu |
| Key Words |
Proprotein convertase subtilisin/kexin type-9 inhibitor; Fatty liver; Nonalcoholic fatty liver disease; Alanine aminotransferase; Aspartate aminotransferase; Imaging |
| Core Tip |
This retrospective study evaluated the effects of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors on fatty infiltration of the liver. Among the 29 selected patients, 11 were found to have radiologic diagnosis of hepatic steatosis and 8 of those (72.73%) achieved complete radiologic resolution of the condition upon use of PCSK9 inhibitors for mean duration of 17.6 mo. Both alanine aminotransferase and aspartate aminotransferase levels showed a downward trend after PCSK9 inhibitors for mean duration of 23.69 ± 11.18 mo. These results highlight the potential benefit of PCSK9 inhibitors use for patients with nonalcoholic fatty liver disease. |
| Publish Date |
2020-12-18 05:58 |
| Citation |
Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1266 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v12.i12.1258 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
